ProKidney (NASDAQ:PROK – Get Free Report) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect ProKidney to post earnings of ($0.13) per share and revenue of $0.1860 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.
ProKidney (NASDAQ:PROK – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts expect ProKidney to post $-0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ProKidney Stock Up 3.5%
Shares of ProKidney stock traded up $0.06 on Tuesday, reaching $1.61. The company’s stock had a trading volume of 327,295 shares, compared to its average volume of 1,002,670. The company has a market capitalization of $487.83 million, a P/E ratio of -3.05 and a beta of 1.61. The stock has a 50-day moving average price of $1.73 and a 200-day moving average price of $1.91. ProKidney has a 52-week low of $1.45 and a 52-week high of $3.48.
Hedge Funds Weigh In On ProKidney
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on PROK shares. HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of ProKidney in a research report on Monday, May 18th. Weiss Ratings upgraded shares of ProKidney from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. Finally, Wall Street Zen cut ProKidney from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, ProKidney currently has an average rating of “Moderate Buy” and a consensus target price of $12.00.
Get Our Latest Research Report on ProKidney
About ProKidney
ProKidney, Inc (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell-based therapies for kidney diseases. The company’s research and development activities center on harnessing human-derived proximal tubule cells to address conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). By targeting the underlying cellular mechanisms of renal injury and dysfunction, ProKidney aims to offer novel regenerative medicine approaches that go beyond current supportive care options.
ProKidney’s lead programs utilize proprietary methods for isolating and expanding renal epithelial cells to create injectable therapeutic products.
Featured Articles
- Five stocks we like better than ProKidney
- Marriott’s Earnings Drop May Be Missing the Bigger Fee Growth Story
- Apple’s AI Strategy Looks Different—Will It Pay Off?
- The AI Chip Stock Making a Quiet Move Toward Dominance
- Why Walmart and Amazon Could Be the Market’s Most Complementary Mega-Caps
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
